Drug products & APIs manufacturers and suppliers in Singapore

Operates a contained small-molecule API facility (around 120,000 sq m) at Tuas Biomedical Park producing APIs for its immunology and oncology pipelines, alongside bulk biologics drug-substance manufacturing on the same campus, with a further US$223 million committed to expand biologics capacity.

Amgen's first Asian manufacturing site at Tuas Biomedical Park, anchored by a next-generation biologics (monoclonal antibody) drug-substance plant integrating multiple process technologies into one facility at a fraction of the footprint, capital and operating cost of a conventional plant, with a chemical-synthesis (small-molecule API) facility alongside it; the site employs 350-plus staff.

A homegrown manufacturer described as Singapore's largest generic-pharmaceutical maker, producing 200-plus therapeutics across multiple finished dosage forms from two PIC/S-GMP plants, with fully integrated contract manufacturing.

A homegrown Singapore CDMO at Ayer Rajah Crescent offering biologics, viral-vector production, cell-therapy manufacturing on its proprietary Tide Motion bioreactor platform, plasmid-DNA manufacturing and small-batch aseptic fill-finish — positioned as Southeast Asia's first small-batch aseptic fill-and-finish service — with an A*STAR bioprocessing partnership.

Operates Singapore's largest vaccines and biologics manufacturing complex at Tuas, and small-molecule chemical and API manufacturing at Jurong and Tuas — historically ten-plus APIs, a Jurong facility deploying continuous and digital manufacturing, and a first-in-Singapore high-potency oncology plant. The Tuas site pairs biologic and vaccine production with small-molecule API.

A roughly US$20 million, ~30,000 sq ft multi-modality vaccine-and-biologics development-and-manufacturing facility at Depot Road (the ACES facility) with end-to-end drug-substance, drug-product and clinical-material capability in isolated single-use suites, focused on mRNA and viral-vector platforms through Phase II; billed as Singapore's only multi-modality vaccine-and-biologics development-and-manufacturing organisation.

A Singapore finished-dose manufacturer producing 300-plus products across tablets, capsules, liquids, creams and injectables at a cGMP facility, with contract and OEM manufacturing via its PharmaKoe arm.

A large mammalian cell-culture CDMO campus at Tuas producing monoclonal antibodies and recombinant and fusion proteins across 20,000-litre stainless-steel and 2,000-litre single-use suites, with cell-line construction through commercial process validation, purification, viral clearance and fill, plus an allogeneic cell-therapy centre of excellence and a strong regulatory-inspection record.

A 72-acre multi-product Tuas hub whose chemical plant has historically produced small-molecule APIs (including etoricoxib and simvastatin), with a US$500 million programme adding sterile fill-finish and secondary packaging for biologic products — KEYTRUDA (pembrolizumab) vials and GARDASIL 9 syringes. Singapore headcount exceeds 1,800.

Operates a biologics drug-substance facility at Tuas built with an investment of over US$500 million — its first biomanufacturing plant in Asia, using cell-culture production — alongside a separate solid-dosage (tablet) small-molecule plant through Novartis Singapore Pharmaceutical Manufacturing (NSPM).

Runs a small-molecule API plant at Tuas Biomedical Park spanning about 22 acres with close to 400 staff, historically producing APIs including gabapentin and pregabalin; a roughly US$743 million extension of the Tuas API plant, and a Jurong Island Manufacturing Technology & Development Centre supporting global process development.

Commercial biologics drug-substance manufacturing at Tuas Biomedical Park, originally established as the Genentech Singapore biologics plant for large-scale mammalian cell-culture production; an anchor Tuas tenant.

A roughly US$590-638 million modular, digitally-enabled vaccine-and-biologics plant at Tuas designed to switch rapidly between up to four vaccines across protein and mRNA platforms — Sanofi's first fully modular vaccine and biologics site in Asia, engineered for pandemic and regional demand, with captive multi-vaccine drug-product filling built in.

Operates a biologic drug-substance plant at Woodlands Industrial Park (distinct from the Tuas cluster), notable for its zero-energy building programme.

Building a roughly US$1.4 billion integrated CRDMO on a 13.5-hectare Tuas site adding 120,000 litres of biologics capacity and about 1,500 jobs, offering end-to-end drug-substance and drug-product (fill-finish) services across monoclonal antibodies, bispecifics and recombinant proteins on single-use technology.